scholarly journals Biological Membrane-Packed Mesenchymal Stem Cells Treat Acute Kidney Disease by Ameliorating Mitochondrial-Related Apoptosis

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Xiaodong Geng ◽  
Quan Hong ◽  
Weiwei Wang ◽  
Wei Zheng ◽  
Ou Li ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Kidney Disease ◽  
Biological Membrane ◽  
Acute Kidney Disease

scholarly journals Klotho and Mesenchymal Stem Cells: A Review on Cell and Gene Therapy for Chronic Kidney Disease and Acute Kidney Disease

Pharmaceutics ◽  
2021 ◽  
Vol 14 (1) ◽  
pp. 11
Author(s):  
Marcella Liciani Franco ◽  
Stephany Beyerstedt ◽  
Érika Bevilaqua Rangel
Keyword(s):  
Chronic Kidney Disease ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Kidney Disease ◽  
Therapeutic Potential ◽  
Financial Burden ◽  
In Vivo Studies ◽  
Promising Therapeutic Approach ◽  
Acute Kidney Disease

Chronic kidney disease (CKD) and acute kidney injury (AKI) are public health problems, and their prevalence rates have increased with the aging of the population. They are associated with the presence of comorbidities, in particular diabetes mellitus and hypertension, resulting in a high financial burden for the health system. Studies have indicated Klotho as a promising therapeutic approach for these conditions. Klotho reduces inflammation, oxidative stress and fibrosis and counter-regulates the renin-angiotensin-aldosterone system. In CKD and AKI, Klotho expression is downregulated from early stages and correlates with disease progression. Therefore, the restoration of its levels, through exogenous or endogenous pathways, has renoprotective effects. An important strategy for administering Klotho is through mesenchymal stem cells (MSCs). In summary, this review comprises in vitro and in vivo studies on the therapeutic potential of Klotho for the treatment of CKD and AKI through the administration of MSCs.

The concurrent therapeutic potential of adipose-derived mesenchymal stem cells on Gentamycin-induced hepatorenal toxicity in rats

2021 ◽  
Vol 16 ◽  
Author(s):  
Mohamed A Rawash ◽  
Ayman Saber Mohamed ◽  
Emad M El-Zayat
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Uric Acid ◽  
Stem Cell ◽  
Kidney Disease ◽  
Therapeutic Potential ◽  
Daily Injection ◽  
Adipose Mesenchymal Stem Cells ◽  
Liver And Kidney ◽  
Therapy Option

Background: Adipose mesenchymal stem cells (AMSCs) are a type of stem cell employed to repair damaged organs. This study aimed to see how effective AMSCs are at treating gentamycin-induced hepatorenal damage in rats. Methods: 18 male Wister rats were assigned into three groups; control, Gentamycin (GM), and GM+AMSCs. GM induced hepatorenal toxicity through daily injection (100 mg/kg, i.p.) for eight days. On day 9, AMSC (106 cells/ml/rat) was injected intravenously. Results : Creatinine, urea, uric acid, AST, ALP, ALT, TNF-, and MDA levels decreased, whereas IL-10, GSH, and CAT levels increased, indicating the therapeutic potency of intravenous injection AMSCs. Conclusion: The current study demonstrated the simultaneous therapeutic efficacy of adipose mesenchymal stem cells on the liver and kidney in the treatment of Gentamycin-induced hepatotoxicity. These data show that AMSCs could be a feasible therapy option for liver and kidney disease.

scholarly journals Combination of Nonwoven Filters and Mesenchymal Stem Cells Reduced Glomerulosclerotic Lesions in Rat Chronic Kidney Disease Models

2019 ◽  
Vol 10 (03) ◽  
pp. 135-149
Author(s):  
Hideo Hori ◽  
Masanori Shinzato ◽  
Yoshiyuki Hiki ◽  
Shigeru Nakai ◽  
Gen Niimi ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Kidney Disease ◽  
Disease Models

scholarly journals Nephroprotective Effect of Mesenchymal Stem Cells in Therapy of Kidney Disease Induced by Toxicant

2020 ◽  
Author(s):  
Shujun Lin ◽  
Wenshan Lin ◽  
Chunling Liao ◽  
Tianbiao Zhou
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Treatment Group ◽  
Kidney Disease ◽  
Drug Toxicity ◽  
Meta Analysis ◽  
Control Group ◽  
The Difference ◽  
And Control ◽  
Nephroprotective Effect

Abstract Background: Renal damage caused by drug toxicity is becoming more and more common in clinic. How to avoid and treat kidney damage caused by drug toxicity is essential to maintain patient health and reduce social economic burden. In this study, we performed a meta-analysis to assess the nephroprotective effect of mesenchymal stem cells (MSCs) in therapy of kidney disease induced by toxicant. Methods: Cochrane Library, Embase, ISI Web of Science and PubMed databases were searched up to Dec 31, 2019 to identify the studies and extract the data to assess the efficacy of MSCs for kidney disease induced by toxicant using Cochrane Review Manager Version 5.3. 27 studies were eligible and recruited for this meta-analysis. Results: The results showed that the difference of Scr between MSCs treatment group and control group was notable for 2 days, 4 days, 5 days, 6-8 days, 10-15 days, ≥42 days (2 days: WMD =-0.88, 95%CI: -1.34, -0.42, P=0.0002; 4 days: WMD=-0.69, 95%CI: -0.99, -0.39, P<0.00001; 5 days: WMD=-0.46, 95%CI: -0.67, -0.25, P<0.0001; 6-8 days: WMD=-0.51, 95%CI: -0.79, -0.22, P=0.0005; 10-15 days: WMD =-0.38, 95%CI: -0.56, -0.20, P<0.0001; ≥42 days: WMD =-0.22, 95%CI: -0.39, -0.06, P=0.007). Furthermore, the difference of BUN between MSCs treatment group and control group was notable for 2-3 days, 4-5 days, 6-8 days, ≥28 days. The results also indicated that MSCs treatment can alleviate the inflammatory cells, necrotic tubule, regenerative tubules, renal interstitial fibrosis in kidney disease induced by toxicant. Conclusion: MSCs might be a promising therapeutic agent for kidney disease induced by toxicant.

scholarly journals P0026METFORMIIN IMPROVES DYSFUNCTION OF MESENCHYMAL STEM CELLS ASSOCIATED WITH CHRONIC KIDNEY DISEASE VIA SENESCENCE INHIBITION

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Hyunjin Noh ◽  
Mi Ra Yu ◽  
Kyoungin Choi ◽  
Dohui Hwang
Keyword(s):  
Chronic Kidney Disease ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Kidney Disease ◽  
Cellular Senescence ◽  
Critical Factor ◽  
Protective Role ◽  
Metformin Treatment ◽  
Promising Source

Abstract Background and Aims Mesenchymal stem cells (MSC) are promising source of cell-based regenerative therapy; however, adequate cell functionality is a critical factor for the success of autotransplantation. Method We investigated the effects of metformin on chronic kidney disease (CKD)-associated cellular senescence using MSC isolated from sham operated and subtotal nephrectomized mice and further explored the protective role of metformin-treated CKD MSC in renal progression. Results When compared to normal MSC, MSC isolated from CKD mice displayed reduced proliferation and early senescence as determined by enlarged cell morphology, increased oxidative stress, accumulation of DNA damage response marker p53 binding protein 1 (53BP1), phospho p53, p16INK4a, and β-gal expression, and decreased cyclin-dependent kinase 4 (CDK4) and cyclin D. CKD MSC exhibited activation of NFκB resulting in expression of senescence-associated secretory phenotype (SASP) factors compared to normal MSC. All of these changes were significantly prevented by metformin treatment. In vivo, metformin-treated CKD MSC attenuated inflammation and fibrosis in UUO kidney as compared to CKD MSC. Co-culture of LPS or TGF-β1-treated HK2 cells with metformin-treated CKD MSC markedly decreased LPS or TGF-β-induced tubular expression of proinflammatory markers and fibrogenesis when compared to CKD MSC suggesting paracrine action of CKD MSC enhanced by metformin treatment. Conclusion Our data suggest that metformin inhibits cellular senescence of CKD MSC and improves their renoprotective effects.

Osteogenic Potency of Secretome Bone Marrow Derived Mesenchymal Stem Cells: A Literature Review

2018 ◽  
Vol 24 (8) ◽  
pp. 6206-6208
Author(s):  
Ismail Hadisoebroto Dilogo ◽  
Jessica Fiolin ◽  
Petrus Aprianto
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Growth Factors ◽  
Bone Healing ◽  
Mechanical Stability ◽  
Healing Process ◽  
Study Groups ◽  
Non Union ◽  
Acute Kidney Disease ◽  
Diamond Concept

Treatment of non-union bone healing has been an unsolved problem in Orthopaedic surgery despite many advances. The most commonly adapted concept is the diamond concept including the osteoprogenitor cells, osteoinductive proteins, osteoconductive scaffolds and mechanical stability. Recent study groups worldwide have been studying the Mesenchymal Stem Cells as an adjunct to increase the bone healing process. However, newer literatures have shown that only few number of MSC transplanted will integrate. This paracrine mechanism is mediated by active secretion of cytokines, growth factors and enzymes called the secretome which is produced as a byproduct during the process of MSC culture. The addition of secretome itself alone is predicted to have the similar effect as the transplantation of MSC with less cost needed, and easier to obtain. The effect of MSC secretome has shown positive result on neurodegenerative disease, acute kidney disease, and cancer; but the effect on bone regeneration itself has never been studied. The MSC secretome have been proven to contain various cytokines (TGβ, some interleukins, GCSF, and many other cytokines) and growth factors (VEGF, EGF, PDGF, IGF-1, IGF-II, PLGF, HGF, NGF, BDNF). We also suspect the osteoinductive profile of MSC secretome due to the existence of BMP-2 which can be analysed using the ELISA spectrophotometry. The osteoinductive profile of secretome MSC will be able to replace the need of recombinant human BMP-2 (rhBMP-2) transplantation in treating bone defect and diminish the risk of excessive inflammation created by BMP-2 and also the carcinogenic potency.

scholarly journals Potential and Therapeutic Efficacy of Cell-based Therapy Using Mesenchymal Stem Cells for Acute/chronic Kidney Disease

2019 ◽  
Vol 20 (7) ◽  
pp. 1619 ◽  
Author(s):  
Chul Yun ◽  
Sang Lee
Keyword(s):  
Chronic Kidney Disease ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Kidney Disease ◽  
Therapeutic Efficacy ◽  
Inflammatory Responses ◽  
Tissue Injury ◽  
Kidney Diseases ◽  
Diverse Range ◽  
Cell Based Therapy

Kidney disease can be either acute kidney injury (AKI) or chronic kidney disease (CKD) and it can lead to the development of functional organ failure. Mesenchymal stem cells (MSCs) are derived from a diverse range of human tissues. They are multipotent and have immunomodulatory effects to assist in the recovery from tissue injury and the inhibition of inflammation. Numerous studies have investigated the feasibility, safety, and efficacy of MSC-based therapies for kidney disease. Although the exact mechanism of MSC-based therapy remains uncertain, their therapeutic value in the treatment of a diverse range of kidney diseases has been studied in clinical trials. The use of MSCs is a promising therapeutic strategy for both acute and chronic kidney disease. The mechanism underlying the effects of MSCs on survival rate after transplantation and functional repair of damaged tissue is still ambiguous. The paracrine effects of MSCs on renal recovery, optimization of the microenvironment for cell survival, and control of inflammatory responses are thought to be related to their interaction with the damaged kidney environment. This review discusses recent experimental and clinical findings related to kidney disease, with a focus on the role of MSCs in kidney disease recovery, differentiation, and microenvironment. The therapeutic efficacy and current applications of MSC-based kidney disease therapies are also discussed.

Sign in / Sign up

Export Citation Format

Share Document